Scarica l'app Stockscreener
15.49
1.71%
0.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$15.23
Aprire:
$15.37
Volume 24 ore:
2.74M
Relative Volume:
1.77
Capitalizzazione di mercato:
$2.26B
Reddito:
$340.81M
Utile/perdita netta:
$-419.65M
Rapporto P/E:
-5.4351
EPS:
-2.85
Flusso di cassa netto:
$-402.10M
1 W Prestazione:
+5.37%
1M Prestazione:
+11.68%
6M Prestazione:
-25.28%
1 anno Prestazione:
-35.16%
Intervallo 1D:
$15.31
$16.19
Intervallo di 1 settimana:
$14.15
$16.19
Portata 52W:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8547
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Confronta DNLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
15.49 | 2.17B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - MSN
Can Denali Therapeutics Inc. Regain Lost Ground This Quarter2025 Price Targets & Smart Swing Trading Alerts - newsyoung.net
Can Denali Therapeutics Inc. be the next market leaderEarnings Risk Report & Safe Capital Growth Tips - thegnnews.com
Is Denali Therapeutics Inc. stock technically oversold2025 EndofYear Setup & Low Drawdown Trading Techniques - sundaytimes.kr
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
Why Denali Therapeutics Shares Are Slipping - TipRanks
Is Denali Therapeutics Inc. subject to activist investor interestTrade Volume Report & AI Optimized Trade Strategies - thegnnews.com
Denali Therapeutics Inc. Stock Approaches Key Moving Average2025 Valuation Update & Community Verified Swing Trade Signals - sundaytimes.kr
Denali Therapeutics COFO Schuth sells $39884 in stock By Investing.com - Investing.com Canada
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - MSN
Denali therapeutics’ Ho Carole sells $52k in stock - Investing.com
Denali Therapeutics COFO Schuth sells $39884 in stock - Investing.com
Science Spotlight: How Denali’s CNS-penetrant amyloid mAb may avoid ARIA - BioCentury
XTX Topco Ltd Lowers Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Elliott Wave Theory Predicts Pullback in Denali Therapeutics Inc.July 2025 Reactions & Community Consensus Picks - beatles.ru
Is now a turning point for Denali Therapeutics Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - Newser
What makes Denali Therapeutics Inc. stock price move sharplyJuly 2025 Earnings & Smart Investment Allocation Insights - Newser
Earnings visualization tools for Denali Therapeutics Inc.Weekly Profit Summary & Weekly Momentum Picks - Newser
Technical signs of recovery in Denali Therapeutics Inc.Dividend Hike & Weekly Consistent Profit Watchlists - Newser
Denali Soars 11% on Biotech Sector Turmoil: What’s Fueling This Surge? - AInvest
Using data filters to optimize entry into Denali Therapeutics Inc.Stock Trading Session Highlights and Summary - Newser
Denali Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowSummary of Consistent Growth Stock Picks - Newser
Denali Therapeutics shares fall 3.52% intraday after reporting mixed Q2 2025 results and regulatory updates. - AInvest
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics: Advancements in CNS Delivery and Strategic Market Positioning Drive Buy Rating - TipRanks
Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating - TipRanks
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports Q2 EPS (72c), consensus (74c) - TipRanks
Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy Rating - TipRanks
Denali Therapeutics Inc. SEC 10-Q Report - TradingView
Denali Therapeutics Q2 2025 Financial Results and Business Highlights: Tividenofusp Alfa BLA Accepted for Priority Review, DNL126 Accelerated Approval Path Aligned, and More. - AInvest
FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan
Possible Bearish Signals With Denali Therapeutics Insiders Disposing Stock - 富途牛牛
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Thursday - Defense World
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - The Globe and Mail
Is Denali Therapeutics Inc. a good long term investmentMaster stock selection with insider knowledge - Jammu Links News
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on momentum stocks before they peak - Jammu Links News
What are Denali Therapeutics Inc. company’s key revenue driversInvest smarter with daily market updates - Jammu Links News
What institutional investors are buying Denali Therapeutics Inc. stockFree Technical Analysis Support - Jammu Links News
What is Denali Therapeutics Inc. company’s growth strategyConsistent triple-digit returns - Jammu Links News
Is Denali Therapeutics Inc. stock overvalued or undervaluedAchieve unparalleled market performance - Jammu Links News
Does Denali Therapeutics Inc. stock perform well during market downturnsMaximize gains with expert trading strategies - Jammu Links News
How does Denali Therapeutics Inc. generate profit in a changing economyMarket-leading profit generation - Jammu Links News
Backtesting results for Denali Therapeutics Inc. trading strategiesForecast Model for Intraday Buy Signals - Newser
How volatile is Denali Therapeutics Inc. stock compared to the marketFree Daily Trading Room Entry - Jammu Links News
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockSky-high return potential - Jammu Links News
Is Denali Therapeutics Inc. a growth stock or a value stockAccelerated financial growth - Jammu Links News
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsInvest smarter with cutting-edge analytics - Jammu Links News
Is it the right time to buy Denali Therapeutics Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Denali Therapeutics Inc Azioni (DNLI) insider trading
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):